Table 1 Clinical characteristics of discovery cohorts
Features | BrM from SYSUCC & QMH (n = 107) | Fukumura K et al. 2021 (n = 31) | GBM from SYSUCC (n = 20) | Duan Hao et al. 2024 (n = 46) | Fischer G et al. 2019 (n = 88) | Routh E et al. 2022 (n = 19) | Wardell C et al. 2021 (n = 65) |
|---|---|---|---|---|---|---|---|
Sex | |||||||
Male, n (%) | 55 (51%) | 10 (32%) | 14 (70%) | 30 (65%) | 53 (60%) | 0 | 33 (51%) |
Female, n (%) | 52 (49%%) | 21 (68%) | 6 (30%) | 16 (35%) | 35 (40%) | 19 (100%) | 32 (49%) |
Primary site | |||||||
Lung | 40 (37%) | 10 (32%) | NA | 46 (100%) | 0 | 0 | 27 (42%) |
Breast | 21 (20%) | 14 (45%) | NA | 0 | 0 | 19 (100%) | 9 (14%) |
Kidney | 8 (7%) | 7 (23%) | NA | 0 | 0 | 0 | 2 (3%) |
Colon | 10 (9%) | 0 | NA | 0 | 0 | 0 | 3 (5%) |
Melanoma | 2 (2%) | 0 | NA | 0 | 88 (100%) | 0 | 14 (22%) |
Other | 26 (24%) | 0 | NA | 0 | 0 | 0 | 10 (15%) |
MGMT | |||||||
Methylated | NA | NA | 7 (35%) | NA | NA | NA | NA |
Unmethylated | NA | NA | 9 (45%) | NA | NA | NA | NA |
Unknown | NA | NA | 4 (20%) | NA | NA | NA | NA |
Age at craniotomy date (years mean (range)) | 58.3 (33.2, 75) | 57.2 (25.6, 78.1) | 47.1 (16.5, 73.3) | 58.4 (29, 76.5) | 52.4 (26, 76) | NA | NA |
Post-operative survival (Craniotomy to censored in month) (months median, (range)) | 26.6 (0.6, 171.2) 5 missing | 25.9 (0.3, 151) | 12.1 (2.7, 25.5) | 28.7 (2.5, 132) 7 missing | 15.7 (0.6, 132.6) | NA | NA |
